Last updated: 2026-09-15 08:00:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $144.51, with a market capitalization of $355.10B and a P/E ratio of 112.63. Over the past 52 weeks, its price has ranged from $77.58 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$355.10B | |
$144.51 | |
$156.92 | |
$15.32 | |
$144.85 | |
16.00 | |
10.33M | |
112.63 | |
$156.92 | |
$77.58 | |
2.32% | |
-- |
Merck & Co., Inc. (MRK) is trading at $146.49 in pre-market trading as of --, up 1.13% ($1.64) from the previous close of $144.85
Pre-market trading shows how investors are pricing MRK before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $152.34 to $144.51, representing a decline of 5.14% ($7.83).
The stock traded between $143.68 and $152.80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7.75 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.4%
MRK is currently trading at $144.51, placing it 84.4% of the way from its 52-week low of $77.58 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.